TriSalus Life Sciences Inc
trisaluslifesci.comWhat Do They Do?
Sells infusion systems for delivering cancer therapies to liver tumors to hospitals, while developing a pancreatic infusion device and an investigational cancer immunotherapy.
10-K for FY2025, filed Mar 5, 2026Our delivery method, Pressure-Enabled Drug Delivery (“PEDD”), modulates pressure and flow within blood vessels to improve intravascular…View ↗
We also have developed a separate 510(k) cleared device for infusions into the pancreas, Pancreatic Retrograde Venous Infusion device…View ↗
We are currently studying the ability of nelitolimod, an investigational class C TLR9 agonist, to reactivate the immune system within the…View ↗
Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospitals…View ↗
How Do They Make Money?
Hospitals and clinics buy PEDD infusion systems, usually through purchase orders; TriSalus is paid when the units ship, or after delivery under some shipping terms. For consigned TriNav, the hospital is billed when the device is used.
10-K for FY2025, filed Mar 5, 2026Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospitals…View ↗
1.Identify the contract — We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to…View ↗
5.Recognize revenue — We recognize revenue at the point-in-time when the units for a purchase order have been shipped and control of the…View ↗
The use of TriNav is consistent with the current steps an interventional radiologist utilizes to conduct TACE and TARE and other…View ↗
$45.2M
-
10-K for FY2025, filed Mar 5, 2026
$45.2M ↗
Who Are Their Customers?
Hospitals and ambulatory surgery centers buy directly through TriSalus’s sales team; interventional radiologists and other hospital clinicians use the products or recommend purchases.
10-K for FY2025, filed Mar 5, 2026We aim to interact closely with all our key stakeholders to ensure a patient’s experience is beneficial. We view our customers as including…View ↗
We have established a commercial infrastructure designed to drive TriNav adoption among interventional radiologists and oncologists. Our…View ↗
Our sales representatives, clinical specialists and sales leaders have substantial medical device sales experience and market our products…View ↗
Do Revenues Turn Into Profits?
No. It lost $39.2M in FY2025.
10-K for FY2025, filed Mar 5, 2026
−$26.9MView ↗
10-K for FY2025, filed Mar 5, 2026
−$39.2MView ↗
10-K for FY2025, filed Mar 5, 2026
−$18.9MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$9.2MView ↗
- ▲ +11% (Loss)
- vs −$8.3M in Q2 FY2025
-
Aug 6, 2026
Maintained full-year revenue guidance
Kept the full-year revenue range at $54 million to $57 million.
Sources
8-K, filed Aug 6, 2026
The Company is maintaining its full-year 2026 revenue guidance of $54 million to $57 million, consistent with the range set in the first…View ↗
From acquisition search to medical devices
The older report described a company seeking a healthcare business combination; the latest describes a medical-device business selling infusion systems and developing an investigational cancer treatment.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 5, 2026We are an early stage blank check company formed on September 11, 2020 as a Delaware corporation for the purpose of effecting an initial…View ↗
Who Do They Compete With?
Competes with Embolix and Merit Medical
10-K for FY2025, filed Mar 5, 2026Microcatheters are manufactured by a wide range of medical device manufacturers. Besides the standard microcatheter, there are two other…View ↗
Loading...
